In July 2018, it was announced that Optivia had been acquired by BioIVT - provider of biological and in vitro products to pharmaceutical and biotechnology organizations. Optivia Biotechnology Inc. provides a suite of transporter biology research and assay services, and products to assist drug development companies in discovering and designing drugs with enhanced therapeutic responses and safety profiles. The company's assay platform includes human transporters, polarized mammalian cells, functional transport assays, and matched control cells, which are used to discover drugs with enhanced bioavailability, tissue selectivity, and fewer drug-drug interactions. It also provides in vitro transporter assay services that include development and discovery compound assay services; and custom assay development services for transporters, including genetic variations. The company offers substrate and inhibition assays for screens or response curves for kinetics. In addition, it provides transporter mediated drug-drug interaction (DDI) assessments to determine whether a compound can cause a drug interaction and whether that compound can fall victim to a drug interaction; OptiDDI suite of FDA compliant DDI assays; substrate transport studies; and inhibition studies. It serves pharmaceutical and biotechnology companies, research institutions, and government agencies.
